Skip to main content
TipRanks
Go Ultimate75% OFF

Gary Titus Insider Profile

4 Followers

Gary Titus, Director at ImmunoCellular Therapeutics, holds 28.00K shares in ImmunoCellular Therapeutics (Ticker: IMUC), holds 37.09K shares in Sciclone Pharmaceuticals (Ticker: SCLN), holds 2.63K shares in Oruka Therapeutics (Ticker: ORKA).

Gary Titus's Trading History

IMUC
ImmunoCellular Therapeutics
Sep 22, 2015DirectorUninformative Buy―$4.40K
SCLN
Sciclone Pharmaceuticals
Jun 18, 2012―Uninformative Buy1.00K$413.61K
ORKA
Oruka Therapeutics
―Chief Acct.Officer―$261.30K

You May Also Like

Gary Titus insider profile FAQ

What is the percentage of profitable transactions made by Gary Titus?
The percentage of profitable transactions made by Gary Titus is 83%.
What is the average return per transaction made by Gary Titus?
The average return per transaction made by Gary Titus is 35.60%.
What stocks does Gary Titus hold?
Gary Titus holds: IMUC, SCLN, ORKA stocks.
What was Gary Titus's most profitable transaction?
Gary Titus’s most profitable transaction was an Informative Buy of SCLN stock on May 26, 2009. The return on the trade was 69.50%.
What is Gary Titus's role in ImmunoCellular Therapeutics?
Gary Titus's role in ImmunoCellular Therapeutics is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.

TipRanks measures corporate insiders by the stock transactions they report to the SEC. See how TipRanks ranks experts and calculates performance.